Image (Abilify 01)
Abilify Asimtufii Injection, Suspension, Extended Release
Product Images NDC 59148-102
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 33 technical images submitted to the FDA as part of the official labeling for Abilify Asimtufii (NDC 59148-102). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Otsuka America Pharmaceutical, Inc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Figure 1 (Abilify 02)
Figure 2 (Abilify 03)
Figure 3 (Abilify 04)
Figure 4 (Abilify 05)
Figure 5 (Abilify 06)
Figure 6 (Abilify 07)
Figure 7 (Abilify 08)
Figure 8 (Abilify 09)
Chemical Structure (Abilify 10)
Figure 9 (Abilify 11)
Figure 10 (Abilify 12)
This text appears to be a list of drugs and their effects on the medication Abilify. It lists inhibitors and inducers of specific enzymes (CYP2D6, CYP3A4) that can affect how Abilify is metabolized in the body. It also includes gastro acid blockers and other drugs such as diazepam. The last line seems to indicate some sort of graph or chart showing the change in Abilify's effectiveness when interacting with these other drugs.*
Figure 11 (Abilify 13)
This text appears to be a list of drugs that can affect the effectiveness of Abilify, a medication used for treating mental health conditions. It provides information on drugs that can inhibit or induce certain enzymes in the body, which can impact the metabolism of Abilify. The list includes the drugs CYRaALInbitor, CYP2DS inhibitor, CYPaAInducer, and Gastrio Acid Bloskers, with some additional names listed under "Other." It also includes information on PK (pharmacokinetics) and a percentage change in relation to a reference point.*
Figure 12 (Abilify 14)
Figure 13 (Abilify 15)
This is a not-available text. It seems to be a fragment of a larger document that contains information about special populations, including those with hepatic impairment and renal impairment. There is also mention of a drug called Avipprazole and a fold change, but the context and meaning of this information are unclear.*
Figure 14 (Abilify 16)
Figure 15 (Abilify 17)
The given text represents a comparative analysis of PANSS (Positive and Negative Syndrome Scale) Total Score changes between ABILIFY MAINTENA and Placebo. The Least-Square Mean Changes in PANNS Total Scores are illustrated for both ABILIFY MAINTENA and Placebo, over 12 weeks of treatment. The analysis includes a sample size of 162-167 participants for ABILIFY and 140-157 participants for Placebo.*
Figure 16 (Abilify 18)
Figure 17 (Abilify 19)
This is a statistical report of the recurrence rate among subjects who participated in a clinical trial for ABILIFY MAINTENA. The table shows the number of subjects at risk at different time intervals and the proportion of subjects who experienced recurrence in both the ABILIFY and PLACEBO group. The duration of time between randomization and recurrence is also provided.*
Image (Abilify 22)
Figure 1 (Abilify 23)
Figure 2 (Abilify 24)
Image (Abilify 25)
Image (Abilify 26)
Figure 3 (Abilify 27)
Figure 4 (Abilify 28)
Figure 5 (Abilify 29)
Figure 6 (Abilify 30)
Figure 7 (Abilify 31)
Figure 8 (Abilify 31a)
Figure 9 (Abilify 32)
Principal Display Panel (720 mg/2.4 mL Syringe Carton)
Abilify Asimtufii is a single-dose prefilled syringe containing 20mg/2.4mL aripiprazole extended-release injectable suspension intended for gluteal intramuscular injection only. It comes with two safety needles - a 1% inch, 22 G needle and a 2 inch, 21 G needle. The recommended dosing frequency is once every two months. Each prefilled syringe contains 300mg/mL of aripiprazole. It contains inactive ingredients such as carboxymethylcellulose, polyethylene glycol 400 (1mg/mL), povidone (4mg/mL), sodium chloride (61mg/mL), sodium phosphate monobasic monohydrate (0.7 mg/mL), and water for injection. It is distributed and marketed by Otsuke America Pharmaceutical, Inc., and marketed by Lundbeck, Deerfiel, IL 60015 USA.*
Principal Display Panel (960 mg/3.2 mL Syringe Carton)
Abilify Asimtufii is a prescription medication that comes in a single-dose prefilled syringe for gluteal intramuscular injection only. The contents include 1 syringe and 2 safety needles. The medication has a concentration of 300 mg/mL and it must be stored between 15°C and 30°C. It is distributed and marketed by Otsuke America Pharmaceutical, Inc and also marketed by Lundbeck.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
